Clinical trial funding to expand the radioisotope medicine chest

June 2, 2021, 7:06AMNuclear News

The Department of Energy is providing up to $2 million in fiscal year 2022 to fund university and national laboratory studies into the use of novel, medically relevant isotopes for use in pre-clinical and clinical medical trials, the DOE’s Office of Science announced on June 1.

Isotope Program: The new funds are being provided as part of the DOE Isotope Program, which produces critical isotopes that would otherwise be unavailable or in short supply for U.S. science, medicine, national security, and industry applications. “This funding will advance research to evaluate new isotopes for use in pre-clinical and clinical trials, with potentially enormous benefits to the field of modern medicine,” said Jehanne Gillo, director of the DOE Isotope Program. While the DOE Isotope Program introduces novel isotopes to the medical community for evaluation, the support of pre-clinical and clinical trials has not been part of the program’s mission.

Eligibility: Isotopes studied “should be at or close to a stage of R&D where questions of utility are beginning to be pondered in earnest,” according to the funding opportunity announcement. Proposals are limited to a list of some 20 potential therapeutic and diagnostic isotopes being developed by the DOE Isotope Program.

Applications, which are due by July 23, are open to all accredited U.S. colleges and universities, national laboratories, nonprofits, and private sector companies. Awards may be made to single investigators as well as to small multi-institutional collaborations.

More information can be found in the funding opportunity announcement issued on June 1 by the Office of Isotope Research and Development and Production within the DOE’s Office of Science.


Related Articles